

**Oxidoreductase disulfide bond proteins DsbA and DsbB
form an active redox pair in *Chlamydia trachomatis*, a
bacterium with disulfide dependent infection and
development**

Signe Christensen^{1, 2, #a}, Maria A. Halili², Natalie Strange³, Guillaume A. Petit², Wilhelmina
M. Huston^{3,*}, Jennifer L. Martin^{2, #b}, and Róisín M. McMahon^{2,*}

¹ Institute for Molecular Bioscience, University of Queensland, St Lucia, Queensland,
Australia

² Griffith Institute for Drug Discovery, Griffith University, Nathan, Queensland, Australia

³ School of Life Sciences, University of Technology Sydney, Broadway, New South Wales,
Australia

^{#a} Current Address: Department of Biochemistry and Structural Biology, Lund University,
Lund, Sweden

^{#b} Current Address: Vice-Chancellor's Unit, University of Wollongong, Northfields Avenue,
Wollongong, New South Wales Australia

* Corresponding author

E-mail: Wilhelmina.Huston@uts.edu.au and roisin.mcmahon@griffith.edu.au

25 **Abstract**

26 *Chlamydia trachomatis* is an obligate intracellular bacterium with a distinctive biphasic
27 developmental cycle that alternates between two distinct cell types; the extracellular
28 infectious elementary body (EB) and the intracellular replicating reticulate body (RB).
29 Members of the genus *Chlamydia* are dependent on the formation and degradation of
30 protein disulfide bonds. Moreover, disulfide cross-linking of EB envelope proteins is critical
31 for the infection phase of the developmental cycle. We have identified in *C. trachomatis* a
32 homologue of the **Disulfide Bond** forming membrane protein *Escherichia coli* (*E. coli*)
33 DsbB (hereafter named CtDsbB) and - using recombinant purified proteins - demonstrated
34 that it is the redox partner of the previously characterised periplasmic oxidase *C.*
35 *trachomatis* Disulfide Bond protein A (CtDsbA). CtDsbA protein was detected in *C.*
36 *trachomatis* inclusion vacuoles at 20 h post infection, with more detected at 32 and similar
37 levels at 44 h post infection as the developmental cycle proceeds. As a redox pair, CtDsbA
38 and CtDsbB largely resemble their homologous counterparts in *E. coli*; CtDsbA is directly
39 oxidised by CtDsbB, in a reaction in which both periplasmic cysteine pairs of CtDsbB are
40 required for complete activity. In our hands, this reaction is slow relative to that observed
41 for *E. coli* equivalents, although this may reflect a non-native expression system and use
42 of a surrogate quinone cofactor. CtDsbA has a second non-catalytic disulfide bond, which
43 has a small stabilising effect on the protein's thermal stability, but which does not appear
44 to influence the interaction of CtDsbA with its partner protein CtDsbB. Expression of
45 CtDsbA during the RB replicative phase and during RB to EB differentiation coincided with
46 the oxidation of the chlamydial outer membrane complex (COMC). Together with our
47 demonstration of an active redox pairing, our findings suggest a potential role for CtDsbA
48 and CtDsbB in the critical disulfide bond formation step in the highly regulated
49 development cycle.

50 Introduction

51 Disulfide bonds add structural bracing to proteins, conferring rigidity and stability. The
52 presence or absence of such structural disulfide bonds varies markedly by cellular
53 compartment. In both bacteria and eukaryotes, structural disulfide bonded proteins are
54 rarely found in the cytoplasm, but instead are prevalent in more oxidising environments. In
55 prokaryotes, disulfide bond proteins are thus found in the periplasm, membrane, and among
56 those proteins secreted into the extracellular environment [1]. This distribution of disulfide-
57 bonded proteins reflects the necessity for additional robustness among these proteins to
58 withstand environmental stresses (e.g. extreme pH, ionic stresses, proteases etc). Many of
59 these disulfide bonded proteins play a role in bacterial pathogenicity. For example, disulfide
60 bonds are required for the function and activity of adhesins [2], proteases [3], toxins [4] and
61 other virulence factors [5, 6] (reviewed in [7] and [1]). Accordingly, bacteria in which
62 members of the protein disulfide oxidative pathway have been deleted show disrupted
63 virulence phenotypes *in vitro* [7-11] and are attenuated in several mouse models of infection
64 [12-14].

65
66 For *Chlamydia* spp, disulfide bonding has additional significance; as well as being required
67 for infectivity [15], disulfide bonding of the outer membrane proteins is cyclically regulated
68 during the bacteria's unique biphasic developmental cycle [15-19] (and reviewed in [20]).
69 Briefly, members of the genus *Chlamydia* alternate between two distinct cell types: the
70 extracellular infectious elementary body (EB) and the intracellular replicating reticulate body
71 (RB). The *Chlamydia* EB is rigid, as a result of substantial disulfide bond cross linking within
72 and between proteins associated with the outer membrane. Collectively these proteins are
73 the Chlamydia Outer Membrane Complex (COMC), comprised of the Major Outer
74 Membrane Protein (MOMP), two cysteine rich proteins (OmcA and OmcB), the polymorphic

75 membrane proteins (Pmps) (except PmpD), PorB, OprB, Pal, Omp85, CTL0887, CTL0645
76 and the type III secretion system components CdsC, CdsD and CdsF. The COMC proteins
77 in the EB envelope are heavily cross-linked with disulfides and this feature is critical for the
78 infectious phase of the bacteria [17-19, 21-23].

79

80 Disulfide bond protein A (DsbA) is the primary oxidase in the disulfide oxidative pathway of
81 bacteria [24]. DsbA catalyses the introduction of disulfide bonds into reduced and folding
82 proteins in concert with a membrane protein partner DsbB. DsbB uses a quinone cofactor
83 as an electron acceptor, and together the DsbA-DsbB pair ultimately shuttle electrons from
84 a reduced protein substrate to molecular oxygen via the respiratory pathway [25, 26].

85

86 *Escherichia coli* DsbA (EcDsbA) was the first DsbA enzyme to be structurally and
87 functionally characterised and serves as the canonical model for DsbA enzymes [24, 27,
88 28]. Briefly, this classic DsbA structure consists of a thioredoxin domain and an inserted α -
89 helical bundle domain. The enzyme's active site is a Cys-Xaa-Xaa-Cys motif located at the
90 N-terminus of helix H1. The sequence of the Xaa-Xaa dipeptide modulates the redox
91 character of the enzyme [29]. The catalytic surface of the protein features 3 loops: Loop 1,
92 (linking helix H1 and β -strand B3), Loop 2 (linking helix H6 and β -strand B4) which contains
93 a highly conserved *cis*Pro residue, and Loop 3 (linking helix H7 and β -strand B5.) Together
94 these loops govern the enzyme's redox properties and its interactions with protein
95 substrates (reviewed in [30] and [31]).

96

97 Structural and biochemical characterisation of a library of bacterial DsbA proteins has
98 revealed that although DsbA proteins from diverse bacterial species share the core structure
99 described for EcDsbA, they exhibit variations in topology and surface features, resulting in

100 structural differences and a nuanced range of redox character and reactivity [31]. This led
101 to description of a classification system of DsbA proteins in which the proteins are broadly
102 divided into two groups: DsbA-I and DsbA-II [31].

103

104 Within the DsbA-II group of DsbA proteins, four proteins have been reported that have a
105 second, non-catalytic disulfide, in addition to the enzymatically critical active site disulfide.
106 These are DsbA proteins from *Pseudomonas aeruginosa* (PaDsbA2 [32]), *Wolbachia*
107 *pipientis* (WpDsbA1 [33]), *Mycobacterium tuberculosis* (MtbDsbA [34, 35]) and *Chlamydia*
108 *trachomatis* (CtDsbA [36]). In each case, this non-catalytic disulfide staples H3 and H5 of
109 the inserted alpha-helix domain. The functional significance of this second bond appears to
110 be variable, with evidence for a potential regulatory role, and influence on redox potential
111 differing between the different enzymes studied to date [32, 33]. While CtDsbA shares
112 common structural and biochemical features with the DsbA-II group of DsbA proteins,
113 especially, CtDsbA shares just 15 % sequence identity with the canonical EcDsbA protein
114 and approximately 20 % sequence identity with other members of the structurally
115 characterised DsbA-II class proteins that contain a second disulfide [36].

116

117 We have previously characterised CtDsbA and shown it to be mildly oxidising (redox
118 potential of -220 mV, compared to that of -120 mV for EcDsbA [36]). Given the importance
119 of disulfide crosslinking of the *Chlamydia* envelope in infection and *Chlamydia* development,
120 we sought to explore the potential role of CtDsbA in chlamydial envelope disulfide bonding.
121 We further sought to query the role of the second non-catalytic disulfide in CtDsbA and
122 identify and characterise CtDsbA's partner protein in *C. trachomatis*.

123

124 Results

125 CtDsbA is expressed early in the *Chlamydial trachomatis* 126 developmental cycle

127 As an initial exploration of the biological role of CtDsbA, we first investigated when in the
128 chlamydial developmental cycle CtDsbA is expressed. Using an antibody generated using
129 recombinant CtDsbA as an antigen, we monitored the expression levels of CtDsbA protein
130 following infection of McCoy B cells within the *C. trachomatis* inclusion vacuole and whole
131 culture extracts (Figs 1 and 2). For Western Blot analysis, antibodies targeting the major
132 outer membrane protein (MOMP) and RNA polymerase beta (RpoB) were used to adjust
133 the loading of whole cell lysates (WCLs) to bring levels at the typically low abundant 20 h PI
134 time point to closer to that of later stages. CtDsbA protein was able to be clearly detected at
135 32 h post infection (h PI) by Western blot (Fig 1). It appears that the CtDsbA protein may
136 also be present at 20 h PI, although the signal is faint. Confocal imaging using the same
137 anti-CtDsbA antibody and a green Alexa Fluor labelled secondary antibody, detected
138 CtDsbA at 20 h post infection but not in the uninfected controls, indicating that some CtDsbA
139 protein is present at this time point (Fig 2). At 32 h and 44 h post infection the expression of
140 CtDsbA is clearly present in the inclusion vacuoles (Fig 2). An antibody specific to *C.*
141 *trachomatis* HtrA (CtHtrA) was additionally used as a positive labelling control, as this
142 antibody has previously been shown to detect *C. trachomatis* at the infection time points
143 analysed [37]. We note that at the 20 h stage of the chlamydial developmental cycle, RB
144 replication is dominant and that the asynchronous conversion to elementary body EB begins
145 around this time, including oxidation of the disulfides in the chlamydial outer membrane
146 complex [38, 39]. Given the possible correlation between CtDsbA expression and onset of
147 disulfide cross-linking of the proteins in the chlamydial envelope, we hypothesised that a

148 DsbA-DsbB redox relay might be involved in the regulation of the disulfide bond status of
149 the chlamydial outer membrane complex and sought to identify a potential DsbB protein in
150 *C. trachomatis*.

151

152 **Fig 1. Detection of DsbA protein in *C. trachomatis* by Western blot.** McCoy B cells were
153 infected with *C. trachomatis* and harvested 20 h, 32 h and 44 h post infection (h PI). CtDsbA
154 was detected by Western blot with an anti-CtDsbA antibody raised in rabbit and a
155 horseradish peroxidase linked secondary antibody (lower left panel). Purified recombinant
156 CtDsbA protein was probed with the same antibodies for reference (right panel). Detection
157 of *Chlamydia* loading control proteins RpoB and MOMP are also shown (upper two panels).
158 The molecular weight (MW) of the protein standards is indicated in kilodaltons (kDa).

159

160 **Fig 2. Detection of DsbA protein in *C. trachomatis* by confocal microscopy.** Confocal
161 images were obtained of *C. trachomatis* infected McCoy B cells harvested at 20 h, 32 h and
162 44 h post infection (h PI), in addition to an uninfected control. CtDsbA and CtHtrA are stained
163 with anti-CtDsbA and anti-CtHtrA antibodies respectively raised in rabbit, with a secondary
164 goat anti-rabbit IgG - Alexa Fluor 488 (green). The host cell nucleus is stained with the
165 fluorescent dye DAPI (blue) that binds strongly to A-T rich regions in DNA. Host cell
166 cytoskeleton is stained with Alexa Fluor 594 Phalloidin (red) that has high affinity for F-actin.

167

168 ***C. trachomatis* encodes a homologue of DsbB**

169 A protein BLAST interrogation of the *C. trachomatis* genome (NCBI Taxid: 813) using *E. coli*
170 DsbB (EcDsbB, UniProt ID P0A6M2) as the query sequence identified a protein of 135
171 amino acids with 22 % sequence identity to EcDsbB (Fig 3). This protein will be referred to
172 hereafter as *C. trachomatis* DsbB (CtDsbB). CtDsbB is predicted to have four

173 transmembrane helices (TM1-4) and two periplasmic loops (P1 and P2), equivalent to the
174 topology of EcDsbB [40, 41]. However, the predicted loop P2 is significantly shortened in
175 CtDsbB (14 residues) relative to its *E. coli* counterpart (49 residues) (Fig 3). CtDsbB has ten
176 cysteine residues compared to six cysteine residues in EcDsbB. Five of the cysteines in
177 CtDsbB are embedded in the predicted transmembrane regions and one is located in the
178 predicted cytoplasmic N-terminal region. Similar to the arrangement of the catalytic
179 cysteines in EcDsbB, the remaining four cysteines are located in the two predicted
180 periplasmic loops, and at the N-terminal end of TM2. In EcDsbB, these 4 cysteines constitute
181 two functional pairs that mediate a series of thiol-exchange reactions facilitating oxidation of
182 EcDsbA. Conservation of Arg48 and Met142, residues proposed to be involved in
183 ubiquinone binding in EcDsbB, suggests that CtDsbB is likewise capable of binding a similar
184 co-factor. The similarity in sequence and topology with EcDsbB suggest that CtDsbB is a
185 redox partner for CtDsbA.

186

187 **Fig 3. Sequence alignment of DsbB from *E. coli* and *C. trachomatis*.** Sequence
188 alignment of EcDsbB and CtDsbB performed in AlignMe [42] and visualised using ESPript
189 [43]. Membrane topology prediction (TMHMM [44]) indicates that CtDsbB (purple), like
190 EcDsbB (blue), has four predicted transmembrane helices, TM1-4 and two predicted
191 periplasmic regions P1 and P2 (indicated with an arrow) each containing two cysteine
192 residues. Annotation of predicted transmembrane boundaries was informed by TMHMM
193 sequence analysis (for both CtDsbB and EcDsbB), and the observation of alpha helices in
194 an available crystal structure (EcDsbB) [40]. Cysteine residues are highlighted in each
195 sequence (purple or blue as above). Residues with strict identity are shown as filled red
196 boxes and a white character. Residues that are highly similar (above the 0.7 equivalence
197 threshold) are shown as red character. Residues with weakly similar properties (below the

198 0.7 equivalence threshold) are shown as black characters. The conserved residues Arg48
199 and Met142 are highlighted with an asterisk.

200 **Membranes containing CtDsbB can sustain CtDsbA catalysed** 201 **oxidation of a model substrate**

202 To test if CtDsbB is indeed a redox partner of CtDsbA, we recombinantly overexpressed
203 CtDsbB in *E. coli*. Crude membrane extracts containing CtDsbB were assayed for their
204 ability to sustain CtDsbA catalysed oxidation of a model peptide substrate. Briefly, in this
205 assay purified DsbA catalyses the oxidation of an intramolecular disulfide bond in an initially
206 reduced and unfolded peptide substrate containing two cysteine residues. Upon folding, a
207 fluorescence signal can be measured between DOTA-europium and coumarin labels on the
208 N and C termini, respectively, of the substrate. 8 μ M CtDsbB in crude *E. coli* membranes
209 successfully sustained CtDsbA (640 nM) oxidase activity (Fig 4A), although at a reduced
210 rate relative to a positive control containing EcDsbA at an 8-fold lower concentration (80 nM
211 EcDsbA and 8 μ M EcDsbB). Essentially no oxidation of the substrate peptide was observed
212 in control reactions containing buffer, CtDsbA, or CtDsbB alone.

213

214 **Fig 4. Both periplasmic disulfide bonds are required for CtDsbB to form a redox relay**

215 **with CtDsbA.** An increase in fluorescence as a function of time is seen as a result of CtDsbA
216 and CtDsbB catalysed oxidation of a fluorescently labelled peptide containing two cysteines.

217 A) A rapid increase in fluorescence is seen for 80 nM EcDsbA with membranes containing
218 8 μ M EcDsbB (green). 640 nM CtDsbA with membranes containing 8 μ M CtDsbB (red) gives
219 a slower increase in fluorescence. Fluorescence only increases minimally for control
220 reactions containing only CtDsbB (8 μ M) membranes (brown), 640 nM CtDsbA (grey) or
221 buffer only (black). B) The increase in fluorescence for 640 nM CtDsbA with membranes
222 containing 8 μ M CtDsbB-CCSS (blue) and 640 nM CtDsbA with membranes containing 8

223 μ M CtDsbB-SSCC (purple) are significantly slower than 640 nM CtDsbA with membranes
224 containing 8 μ M CtDsbB (red), but marginally faster than 640 nM CtDsbA with membranes
225 containing 8 μ M BpsDsbB-SSSS (pink) and buffer only (black). The curves for 80 nM
226 EcDsbA with membranes containing 8 μ M EcDsbB (green), 640 nM CtDsbA with
227 membranes containing 8 μ M CtDsbB (red) and buffer only (black) are the same as in A.
228 Plotted data show mean and SD for two biological replicates.

229

230 In *E. coli* both periplasmic loop cysteine pairs of EcDsbB participate in the mechanism of
231 EcDsbA oxidation [45-47]. To investigate whether the mechanism of CtDsbA oxidation by
232 CtDsbB is similar to that of *E. coli*, two CtDsbB mutants were designed in which the cysteines
233 in loop P1 and loop P2, respectively, are mutated to serines. In CtDsbB-SSCC, periplasmic
234 loop 1 Cys36 and Cys39 are mutated to serines. In CtDsbB-CCSS, periplasmic loop 2 Cys98
235 and Cys104 are mutated to serines. In the presence of CtDsbB-CCSS or CtDsbB-SSCC,
236 CtDsbA catalysed oxidation of the peptide substrate is markedly reduced relative to wild-
237 type CtDsbB, although oxidation proceeds more rapidly than observed for negative controls
238 containing only buffer, or the wild-type CtDsbB variant alone (Fig 4B). That CtDsbA is
239 significantly less active in the presence of CtDsbB-SSCC or CtDsbB-CCSS, than in the
240 presence of CtDsbB, suggests that as anticipated, the disulfide bonds present in periplasmic
241 loops P1 and P2 are each required for complete oxidation of CtDsbA.

242

243 Although much less active than in the presence of CtDsbB, reactions of CtDsbA with
244 membranes containing CtDsbB-SSCC and CtDsbB-CCSS did show some activity relative
245 to the buffer control (Fig 4B). To exclude the possibility that other factors present in the *E.*
246 *coli* membranes facilitate CtDsbA activity, a catalytically inactive construct of a DsbB from
247 another organism, *Burkholderia pseudomallei* with all four cysteines in the two periplasmic

248 loops mutated to serines (BpsDsbB-SSSS)[13] was included as a negative control (Fig 4B).
249 Membranes containing catalytically inactive BpsDsbB-SSSS were also unable to facilitate
250 CtDsbA activity, and most closely resembled the reaction containing buffer alone.
251 Consequently, the observed CtDsbA activity arises from a specific interaction with CtDsbB,
252 and other factors in the membrane preparation contribute minimally to CtDsbA activity.
253 Taken together, this activity is consistent with CtDsbB being a redox partner protein of
254 CtDsbA.

255

256 **Detergent solubilised, purified CtDsbB partially oxidises** 257 **reduced CtDsbA**

258 To confirm that CtDsbA oxidising activity in the model substrate assay is sustained
259 specifically by interaction with CtDsbB in the membranes, we examined the redox state of
260 recombinant purified CtDsbA following incubation with detergent solubilised purified
261 CtDsbB. The redox state of CtDsbA was assessed using an electrophoretic mobility assay.
262 Briefly, CtDsbA was treated with the thiol-reactive probe 4-Acetamido-4'-
263 Maleimidylstilbene`-2,2'-Disulfonic Acid (AMS), which labels free thiols and adds 0.5 kDa
264 per label to the molecular weight. This allows oxidised CtDsbA and reduced CtDsbA to be
265 separated by SDS-PAGE, and their relative abundance quantified by densitometric analysis.

266

267 As we hypothesised that the active site CSAC thiols are the likely target for CtDsbB
268 mediated oxidation, we first used a construct of CtDsbA in which the three non-catalytic
269 cysteines in the protein were changed to serine (CtDsbA-SSS; [36]) Reduced CtDsbA-SSS
270 was incubated with ubiquinone-1 (UQ1) in the presence or absence of equimolar amounts
271 of purified, detergent-solubilised CtDsbB. After mixing, a sample was taken immediately,
272 and after subsequent time points, as indicated in Fig 5. At each time point the reaction was

273 stopped by precipitation with trichloroacetic acid (10% w/v) and the samples subsequently
274 treated with AMS.

275

276 **Fig 5. Detergent solubilised, purified CtDsbB partially oxidises CtDsbA-SSS**
277 **independently of exogenous ubiquinone.** The redox state of CtDsbA-SSS over time was
278 monitored by a shift in electrophoretic mobility after treatment with the alkylating agent AMS
279 that adds 0.5 kDa per reduced cysteine. A) Reduced CtDsbA-SSS (15 μ M) was incubated
280 with equimolar purified detergent solubilised CtDsbB (15 μ M) in the absence or presence of
281 UQ1 (15 μ M) and incubated over the indicated time course. Oxidised CtDsbA-SSS is
282 detectable after 10 min in the presence of CtDsbB (left hand side of gel) and was not affected
283 by the addition of exogenous UQ1 (right hand side of gel). Completely reduced and oxidised
284 CtDsbA-SSS protein samples were included on the SDS-PAGE for reference. These
285 samples contained 5mM DTT and 5 mM oxidised glutathione respectively to keep CtDsbA-
286 SSS reduced and oxidised throughout the 120 min incubation. Incubation of reduced
287 CtDsbA-SSS with 15 μ M UQ1 showed a small fraction of oxidised CtDsbA-SSS formed over
288 the 120 min time course. Data presented is representative of three independent experiments
289 from three different purifications of recombinant CtDsbA-SSS and CtDsbB, expressed
290 following independent transformations of *E. coli*.

291

292 For CtDsbA-SSS incubated with CtDsbB and UQ1, the protein initially migrates at a
293 molecular weight corresponding to reduced CtDsbA-SSS (red CtDsbA-SSS) until 10
294 minutes after the reaction is started, at which point CtDsbA-SSS migrates as two bands,
295 corresponding to a mixture of oxidised (ox CtDsbA-SSS) and reduced protein. After 120
296 min, only half of the CtDsbA-SSS has been oxidised by CtDsbB in the presence of
297 exogenous UQ1 (Fig 5). This reaction proceeds slowly as compared to EcDsbA and EcDsbB

298 where in an equivalent experiment in the presence of exogenous UQ1, essentially all
299 reduced EcDsbA is converted to the oxidised form in 10 seconds, with a minor population
300 participating in the formation of a EcDsbA-EcDsbB complex [48]. Of note, in our hands the
301 oxidation of reduced CtDsbA-SSS proceeds similarly in the presence and absence of
302 exogenous UQ1, suggesting that exogenous UQ1 is not required for the reaction to proceed,
303 although in neither case is reduced CtDsbA-SSS fully converted to oxidised over the 120
304 min period. Notably, when reduced CtDsbA-SSS was incubated in the presence of UQ1
305 alone i.e. without DsbB, a small fraction of CtDsbA-SSS was oxidised over the time course
306 (120 min.) Taken together with the model substrate oxidation, these data suggest that
307 CtDsbA and CtDsbB can form a functional relay, although UQ1 is likely not the ideal quinone
308 for the reaction as evidenced by the relatively slow rates of reaction and that the redox
309 conversion does not go to completion under the experimental conditions used.

310 **Unpicking the role of the second disulfide in CtDsbA**

311 Next, we investigated the contribution of the second disulfide bond to CtDsbA's redox
312 character and activity. In *Wolbachia pipientis* DsbA1 (WpDsbA1), an equivalent non-
313 catalytic secondary disulfide may have a regulatory role by autoinhibiting the interaction of
314 WpDsbA1 with its partner *W. pipientis* DsbB [49], and a very modest effect on redox potential
315 [33]. In contrast, mutation of the secondary disulfide in *P. aeruginosa* PaDsbA2 influences
316 the protein's redox potential significantly [32]. We sought to answer what role this second
317 disulfide may play in CtDsbA, by investigating whether its removal affected CtDsbA's
318 interaction with CtDsbB, or altered the protein's thermal stability of its reduced and oxidised
319 states.

320

321 To explore the potential for the second disulfide to modulate interaction with CtDsbB, we
322 compared the activity of CtDsbA-SSS (containing only the active site disulfide) and wild type

CtDsbA (containing both the active site, secondary disulfide and an unpaired cysteine) in the model peptide substrate assay. CtDsbA-SSS and wild-type CtDsbA are equally active in their oxidation of the model substrate, suggesting that the second disulfide does not affect interaction with CtDsbB in this assay, at least not in the presence of the endogenous quinone available in the membrane preparation (Fig 6A). We note the possibility that addition of an exogenous ideal quinone may reveal reaction differences between the protein variants.

329

Fig 6. The second disulfide of CtDsbA does not influence interaction with CtDsbB. A)

An increase in fluorescence as a function of time is seen as a result of CtDsbA or CtDsbA-SSS catalysed oxidation of a fluorescently labelled peptide containing two cysteines. A rapid increase in fluorescence is seen for positive control 80 nM EcDsbA with membranes containing 8 μ M EcDsbB (green). The activity of 640 nM CtDsbA (red) and 640 nM CtDsbA-SSS (blue) is equivalent upon interaction with membranes containing 8 μ M CtDsbB. The activity of CtDsbB (grey) is only minimally higher than fluorescence for the buffer only control (black). Plotted data show mean and SD for three biological replicates, except for the EcDsbA + EcDsbB control where data from a single experiment was used. B) Reduced CtDsbA (15 μ M) was incubated with equimolar purified detergent solubilised CtDsbB (15 μ M) in the absence or presence of UQ1 (15 μ M) and incubated over the indicated time course. Oxidised CtDsbA was detected after 10 min in the presence of CtDsbB (left hand side of gel) and did not require exogenous UQ1 for the reaction to proceed (right hand side of gel). Completely reduced and oxidised CtDsbA-SSS protein samples were included on the SDS-PAGE for reference. These samples contained 5mM DTT and 5 mM oxidised glutathione respectively to keep CtDsbA-SSS reduced and oxidised throughout the 120 min incubation. 15 μ M UQ1 alone was not able to oxidise CtDsbA over the 120 min time course. Data presented is representative of three independent experiments from three different

348 purifications of recombinant CtDsbA and CtDsbB expressed following independent
349 transformations of *E. coli*.

350

351 Similarly, we assessed whether CtDsbB mediated oxidation of reduced wild type CtDsbA
352 and reduced CtDsbA-SSS proceeded equivalently using the electrophoretic mobility assay.
353 We showed previously that detergent solubilised CtDsbB was able to oxidise CtDsbA-SSS
354 without the addition of exogenous UQ1 (Fig 5). Here, CtDsbB was also able to oxidise
355 reduced wild type CtDsbA in the presence or absence of exogenous UQ1 (Fig 6B), indicating
356 that exogenous UQ1 is not required for the reaction to proceed. Once again, under these
357 experimental conditions, a mixture of oxidised and reduced CtDsbA remained after 120 min.
358 One difference however, was that reduced wild type CtDsbA was not readily oxidised by
359 exogenous UQ1 alone, indicating that the oxidation reaction is predominantly mediated by
360 CtDsbB.

361

362 Reduction and oxidation of disulfide bonds in proteins can change a protein's melting
363 temperature (T_m), i.e. the temperature at which half of the protein is unfolded. Typically, in
364 DsbA proteins, reduction of the active site disulfide increases the melting temperature,
365 reflecting the greater stability of the reduced form of the protein relative to the oxidised form,
366 consistent with a thermodynamic favourability for the enzyme to oxidise substrates and itself
367 become reduced. We have previously determined the melting temperature for reduced and
368 oxidised CtDsbA as 339 ± 0.2 K and 335 ± 0.1 K, respectively; this is one of the smaller
369 differential T_m values reported for DsbA proteins [36]. The melting temperature of reduced
370 CtDsbA-SSS was determined as for wild-type using a gradual temperature ramp and
371 monitoring protein unfolding by circular dichroism spectroscopy. The melting temperature of
372 reduced CtDsbA-SSS was determined as $336\text{K} \pm 0.1$, and that of the oxidised state 334K

373 ± 0.2 (Fig 7). As for other DsbA proteins, the melting temperature of the reduced protein is
374 greater, indicating that the reduced state has a greater thermal stability than the oxidised
375 state. As only the active site disulfide can form in this construct, this is consistent with the
376 relative thermodynamically favoured reduced state of the enzyme. The difference in T_m
377 between the two states is again modest (~ 2 K), and indeed smaller than that observed for
378 wild-type protein (4 K [36]).

379

380 **Fig 7. The second disulfide of CtDsbA has a limited effect on protein thermal stability.**

381 The thermal unfolding of reduced and oxidised CtDsbA-SSS was monitored by CD
382 spectroscopy and the fraction of unfolded CtDsbA-SSS plotted as a function of temperature.
383 With a melting temperature of $336 \text{ K} \pm 0.1$, reduced CtDsbA-SSS is slightly more stable than
384 oxidised CtDsbA-SSS that has a melting temperature of $334 \text{ K} \pm 0.2$. Plotted data show
385 mean and SD for three biological replicates.

386

387 The reduced difference in T_m between the reduced and oxidised states of CtDsbA-SSS
388 ($\Delta T_m = 2$ K), compared to reduced and oxidised CtDsbA ($\Delta T_m = 4$ K) suggests that the non-
389 catalytic disulfide contributes somewhat to the relative stability of the oxidised and reduced
390 states i.e. either by additionally stabilising the reduced form, or further destabilising the
391 oxidised.

392

393 As reduced wild type CtDsbA (in which both active site and non-catalytic disulfides are
394 reduced) and reduced CtDsbA-SSS (in which the active site disulfide is reduced, and the
395 reduced second disulfide is mimicked by cysteine-to-serine mutations) both represent
396 proteins in which both disulfides are effectively in the reduced state, it was surprising that
397 the melting temperature for reduced CtDsbA-SSS differs from that of reduced wild type

398 CtDsbA : 339 ± 0.2 K (reduced wild-type CtDsbA) and $336 \text{K} \pm 0.1$ (reduced CtDsbA-SSS)
399 (Table 1). This is most likely a result of differences in the biochemical properties of the serine
400 compared to the reduced cysteine residue that it replaces. Together these mutations may
401 additionally alter the overall stability of CtDsbA-SSS and contribute to the difference in
402 melting temperature of reduced CtDsbA-SSS relative to reduced CtDsbA.

403

404 **Table 1. Melting temperatures of CtDsbA redox states.**

	T _m (K) reduced	T _m (K) oxidized	ΔT _m (K)
CtDsbA	339±0.2	335±0.1	4
CtDsbA-SSS	336±0.1	334±0.2	2

405 The melting temperatures (T_m) of reduced and oxidised CtDsbA were determined
406 previously [36]. T_m values for CtDsbA-SSS are from this study. Mean and SD for three
407 biological replicates are presented.

408

409

410 Discussion

411 We have identified a DsbB protein in *C. trachomatis*, and demonstrated that it is a redox
412 partner of the previously characterised oxidase CtDsbA [36]. As a redox pair CtDsbA and
413 CtDsbB largely resemble their homologous counterparts in *E. coli*: CtDsbA is directly
414 oxidised by CtDsbB in a reaction in which both periplasmic cysteine pairs of CtDsbB are
415 required for activity. We showed that this reaction proceeded independent of exogenously
416 added ubiquinone, but more slowly than the EcDsbA-EcDsbB interaction and did not go to
417 completion. Whilst these data demonstrate that CtDsbA and CtDsbB form a redox relay,
418 they suggest that the native CtDsbB co-factor is not UQ1 or Ubiquinone-8 (UQ8) (the
419 endogenous ubiquinone in *E. coli*).

420

421 A notable difference from the canonical *E. coli* system in *C. trachomatis* is the presence of
422 a second non-catalytic disulfide bond in CtDsbA. This disulfide bond, bridging helices H2
423 and H5 of the protein, is conserved in DsbAs from alpha-proteobacteria including *W.*
424 *pipientis* [49]. It is also found in the DsbA from *M. tuberculosis* [34] and one of the two DsbAs
425 (PaDsbA2) encoded by *P. aeruginosa* [32]. In *W. pipientis*, this second disulfide has a
426 modest effect on redox potential [33] but appears to inhibit the WpDsbA interaction with
427 WpDsbB [49]. By contrast, the additional disulfide bond of PaDsbA2 does modulate the
428 protein's redox potential [32]. For CtDsbA, we found that this second disulfide bond has no
429 effect on CtDsbA activity or its interaction with CtDsbB but may contribute to the relative
430 stability of the active site redox forms of the enzyme.

431

432 Reduced EcDsbA is partially oxidised immediately upon addition of EcDsbB and UQ1, and
433 becomes fully oxidised after 10 seconds [48]. We observe a similar trend for the *Chlamydia*
434 proteins, supporting the observation that CtDsbA and CtDsbB are partners, but conclude

435 also that the reaction is not optimal under the experimental conditions we used. This may
436 reflect the fact that the proteins were expressed recombinantly in a non-native *E. coli* host.

437

438 Inaba *et al* have reported that a quinone-free preparation of EcDsbB oxidises ~40% of
439 EcDsbA in a 1:1 stoichiometric reaction [48]. This may also be the case for the *Chlamydia*
440 DsbA/B system as we found that about half of reduced CtDsbA or CtDsbA-SSS is oxidised
441 by CtDsbB in a 1:1 ratio. The addition of exogenous UQ1 to the CtDsbB reaction had no
442 further effect, indicating that UQ1 or endogenous UQ8 (presumed to be present in *E. coli*
443 membranes), may not be its optimal cofactor.

444

445 Members of the *Chlamydia* genus are Gram negative obligate intracellular bacteria with a
446 biphasic development cycle. In this cycle, *Chlamydia* alternates between two different cell
447 types, the infectious extracellular EB and the intracellular RB, although this is highly
448 asynchronous. After the infectious EBs have been internalised by host eukaryotic cells, the
449 EBs differentiate to RBs (2-8 h post infection). The RBs subsequently replicate (8-24 h),
450 before re-differentiating to EBs (24-72 h) in preparation for cell lysis or vacuole extrusion
451 and release (40-72 h), ready for the next infectious event. Confocal microscopy with
452 immunofluorescence detected CtDsbA in *C. trachomatis* from at least 20 h post infection
453 onwards (also observed by Western blot). The 20 h time point represents the middle to late
454 replicative phase of the *Chlamydia* biphasic lifecycle, when the recently differentiated RBs
455 multiply. A previous transcriptional profiling study reported that CtDsbA gene expression
456 begins as soon as 8 hours post infection [50], corresponding to late EB to RB differentiation
457 and early RB replication. We were able to detect DsbA at 20 h PI using immunofluorescence
458 microscopy, and a faint band via Western blot. The low levels of CtDsbA protein detected at
459 20 h post infection could arise from the use of different strains in the two studies (*C.*

460 *trachomatis* serovar D strain UW-3/Cx in the transcriptional study compared to *C.*
461 *trachomatis* LGV-2 used here), but more likely reflects a difference in methodology for
462 detecting CtDsbA (transcript versus protein). Factors such as mRNA stability, protein
463 degradation, and variable transcription and translation rates, mean that mRNA expression
464 levels can differ by up to 60% from protein levels in eukaryotes and prokaryotes [51, 52]. A
465 third study measured CtDsbA protein levels by label-free quantitative proteomics and found
466 no DsbA in replicating RBs 18 h post infection, but did detect CtDsbA in EBs 44 h post
467 infection, around the time of asynchronous exit from the host cell [53]. In our hands, CtDsbA
468 protein levels increased markedly between 20 and 32 h PI and remained at a high level at
469 44 h post infection. In summary, CtDsbA protein was detectable at 20 h post infection,
470 although CtDsbA transcription onset may precede this by up to 12 hours.

471

472 Within the *C. trachomatis* COMC, the MOMP is synthesised early in the replicative phase
473 but is not oxidised until the onset of RB to EB differentiation (at approximately 24 h post
474 infection) [22, 38, 39, 50, 54, 55]. The two cysteine-rich proteins, OmcA and OmcB are
475 synthesised late in the replicative phase (up to 24 h post infection) but are oxidised
476 immediately [22, 38, 39, 50, 54]. The coincidence of CtDsbA expression and the onset of
477 COMC protein oxidation is notable, and could support the notion that the COMC is one
478 possible substrate of CtDsbA. DsbJ and DsbH are also likely to be important contributors to
479 the COMC protein redox status. The expansion of the number of genes encoding for
480 oxidoreductases in *Chlamydia* is likely due to the critical role that redox status has on the
481 developmental cycle, mediated by the COMC. Presumably given the reduced genome
482 nature of this organism, the oxidoreductases are likely all critical. It is possible that individual
483 proteins have specialised substrate selectivity or, given how critical the redox status of the

484 COMC is for the biology of this organism, that there is functional redundancy, although the
485 precise function of individual oxidoreductases in *Chlamydia* is currently unknown [20].

486

487 Disulfide-dependent infection and development is a unique feature of *Chlamydia*, though
488 the suite of Dsb proteins in *Chlamydia* are, with the exception of DsbJ, present in other
489 bacteria (reviewed in [20]). Continued elucidation of the intricacies of *Chlamydia* Dsb
490 proteins, their substrates, and their interaction will help us to understand the critical yet
491 incompletely characterized role of disulfide bonding in the *Chlamydia* infection lifecycle.

492

493 **Materials and Methods**

494 **Investigation of CtDsbA expression levels by Western blot**

495 McCoy B (sourced from American Tissue Culture Collection (ATCC): CRL 1696, mouse
496 fibroblast like immortalised cells) cells were cultured in 6-well plates at 300,000 cells per
497 well in 3 mL of culture media (high glucose Dulbecco's Modified Eagle Medium (DMEM;
498 Sigma-Aldrich D6546) supplemented with heat-inactivated 10% foetal calf serum, 4 mM L-
499 Glutamine, 100 µg/mL streptomycin and 50 µg/mL gentamycin) and incubated at 37°C with
500 5% CO₂. 24 hours after seeding, cells were infected with *C. trachomatis* LGV-2 (strain
501 443/Bu, sourced from the ATCC: VR-902B) at a multiplicity of infection of 1. The infected
502 cells were rocked for 30 mins to disperse infectious units, then centrifuged at 500 × g for 30
503 mins to synchronise the infection, prior to a media change at 4 h post infection (h PI) with
504 the addition of 1 µg/mL cycloheximide. Uninfected controls were cultured in the same
505 manner except non-infectious media was added at 24 h after seeding. Infected wells were
506 harvested into SPG (10 mM sodium phosphate, 250 mM sucrose, 5 mM L-glutamate) via
507 scraping at 20, 32 and 44 h PI, and uninfected wells were harvested at 44 h PI only. Two
508 sets of triplicate wells were pooled for each sample and immediately added to 4x Bolt LDS
509 Sample Buffer (Invitrogen; lithium dodecyl sulfate at pH 8.4) to give a final concentration of
510 1x sample buffer and 50 mM dithiothreitol (DTT), and boiled at 99°C for 20 mins to lyse.
511 Independent experiments were repeated on three separate occasions. A representative
512 example Western blot is shown in the results. For Western blot analysis samples were
513 separated by SDS-PAGE using Bolt 4-12% Bis-Tris gels (ThermoFisher) in MES SDS
514 running buffer (50 mM MES, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.3) at 200 V
515 for 20 min. Following electrophoresis, proteins were transferred onto a nitrocellulose
516 membrane using an iBlot 2 transfer device (ThermoFisher). Proteins were probed with an

517 anti-CtDsbA antibody from serum harvested from a rabbit immunised with purified
518 recombinant CtDsbA protein (purchased from Osenses). The serum containing anti-CtDsbA
519 antibody was prepared as a 1:400 dilution in 1% skim milk powder in TBS (50 mM Tris-Cl,
520 pH 7.6, 150 mM NaCl). An anti-RpoB antibody (*Chlamydia* loading control, MyBioSource)
521 was similarly prepared in a 1:20,000 dilution, and anti-MOMP (second *Chlamydia* loading
522 control, Invitrogen) was prepared as a 1:5000 dilution. Anti-rabbit IgG, or anti-mouse IgG
523 coupled with horse radish peroxidase were applied as a secondary antibody (1:10,000
524 dilution in 1% skim milk powder in TBS) and the final bound protein detected using enhanced
525 chemiluminescence (Amersham ECL Prime Western Blotting Detection Reagent, GE
526 Healthcare) and an Amersham AI600 imager (GE Healthcare).

527

528 **Investigation of CtDsbA protein by confocal microscopy**

529 At 20, 32 and 44 h post infection, coverslip cultures of McCoy B cells infected with *C.*
530 *trachomatis* LGV-2 were fixed with 4% PFA for 10 min. Cultures were stained with the anti-
531 CtDsbA antibody used for the Western blot analysis, and a secondary goat anti-rabbit IgG
532 antibody conjugated with Alexa Flour 488. Positive labelling controls were stained with anti-
533 CtHtrA antibody raised in rabbit and the same secondary used against anti-CtDsbA. The
534 host cell nucleus was stained with 4',6-diamidino-2-phenylindole (DAPI), and the host cell
535 cytoskeleton was stained with Alexa Fluor 594 Phalloidin. Coverslips were mounted on
536 slides in Prolong Gold (Invitrogen) prior to immunofluorescence imaging on a Nikon A1
537 confocal LASER microscope.

538

539 **Expression and purification of CtDsbA and variants**

540 The recombinant CtDsbA used in this study corresponds to residues 34-238 of *C.*
541 *trachomatis* dsbA as reported previously [36]. CtDsbA-SSS is a variant in which each of
542 three non-active cysteines are mutated to serine (C66S, C80S and C141S). CtDsbA and
543 CtDsbA-SSS were expressed in *E. coli* BL21 (DE3) pLysS (Invitrogen) and purified as
544 described in [36] with one modification; to improve stability of the protein the buffer was
545 changed to 25 mM Tris pH 7.4, 150 mM NaCl. As required CtDsbA and CtDsbA-SSS were
546 reduced and oxidised by incubation with 100-fold molar excess of dithiothreitol (DTT) or 100
547 fold molar excess of oxidised glutathione, respectively. The protein redox state was
548 confirmed by Ellman's reagent [56].

549

550 **Expression and preparation of membranes containing CtDsbB** 551 **and variants**

552 CtDsbB (Uniprot ID 084179) was identified by homology to EcDsbB (Fig 3). Additional
553 CtDsbB variants in which pairs of cysteine residues in each of the periplasmic loops were
554 mutated to serine were also designed: namely CtDsbB-SSCC (C36S and C39S in
555 periplasmic loop 1) and CtDsbB-CCSS (C98S and C104S in periplasmic loop 2). The DNA
556 for CtDsbB and mutants were purchased as gBlocks (Integrated DNA technologies) with a
557 5' XhoI and a 3' NdeI restriction site for insertion to a pET21a vector. This added a non-
558 cleavable C-terminal His6 tag.

559

560 All constructs were expressed in *E. coli* C41(DE3) (kindly provided by Cy Jeffries, University
561 of Sydney) cells using PASM 5052 autoinduction media [57] containing ampicillin and
562 incubated at 30°C for 18-24 h with orbital shaking at 200 rpm. Cells were harvested by
563 centrifugation at 6,000 rpm for 15 mins. Harvested cells were resuspended in 25 mM 2-(N-
24

564 morpholino) ethanesulfonic acid (MES) buffer at pH 6, 150 mM NaCl and lysed using a cell
565 disrupter (Constant Systems Ltd) (one passage at 28 KPsi followed by a second passage
566 at 30 KPsi). Unbroken cells and debris were removed by centrifugation at 18,500 rpm for 30
567 mins. Membranes were harvested from the supernatant by ultracentrifugation (42,000 rpm
568 for 1 hr) at 4°C. The pellet was resuspended in 25 mM MES pH 6, 150 mM NaCl using a
569 glass dounce homogeniser.

570

571 For the model substrate folding assay, the amount of CtDsbB present in the crude
572 membranes was quantified by SDS-PAGE analysis, in comparison to a series of known
573 amounts of detergent solubilised purified EcDsbB (0, 0.5, 1, 2 and 5 µg). A series of dilutions
574 of the membrane preparation were prepared in sample loading dye alongside EcDsbB
575 standards, and densitometric analysis and comparison of the bands used to estimate the
576 concentration of CtDsbB in the membrane preparations.

577

578 **Solubilisation and purification of CtDsbB**

579 Crude membranes containing CtDsbB were solubilised in 25 mM MES pH 6, 150 mM NaCl
580 with 0.5 % DDM under vigorous stirring at 4°C for 1 h. Solubilised protein was isolated by
581 ultracentrifugation for 1 h at 42,000 rpm at 4°C, and the supernatant loaded onto a 5 mL
582 HisTrap™ HP column (GE Healthcare) equilibrated in 25 mM MES pH 6, 150 mM NaCl with
583 0.015 % DDM (Buffer 1). The column was washed with Buffer 1 plus 20 mM imidazole (10
584 x column volume (CV)), with sequential washes of 40 mM imidazole (10 x CV), 80 mM
585 imidazole (10 x CV), 120 mM imidazole (5 x CV) and eluted with 500 mM imidazole (5 x
586 CV). The eluted protein has a distinctive orange colour, suggesting a bound ubiquinone
587 cofactor [48]. Protein was further purified by size exclusion chromatography using a
588 Superdex™ 200 16/60 column (GE Healthcare) in Buffer 1. Protein purity was evaluated by

25

589 SDS-PAGE on a NuPAGE 12% Bis-Tris gel (ThermoFisher) with MES running buffer (50 mM
590 MES pH 7.3, 50 mM Tris, 0.1% sodium dodecyl sulfate (SDS) and 1 mM
591 Ethylenediaminetetraacetic acid (EDTA)).

592 **Model substrate folding assay**

593 The peptide oxidation assay was performed as reported in [36] except that crude
594 membranes containing recombinant CtDsbB were used instead of oxidised glutathione to
595 sustain CtDsbA activity. Briefly the assay was performed in a 384-well plate (Perkin Elmer,
596 USA). A solution of 50 mM MES, 50 mM NaCl, 2 mM EDTA, pH 5.5, 8 μ M of the DsbB and
597 either 80 nM (EcDsbA) or 640 nM (CtDsbA or CtDsbA-SSS) were added to the wells in a
598 total volume of 25 μ L. Adding 25 μ L peptide to a final concentration of 10 μ M started the
599 reaction. Change in fluorescence was monitored at excitation 340 nm and emission 615 nm,
600 with a delay of 100 μ s and read time of 100 μ s, using a Synergy H1 Multimode plate reader
601 (BioTek, USA). Plotted data shows mean and SD for two biological replicates.

602

603 **Redox state of analysis of reduced CtDsbA and CtDsbA-SSS in** 604 **the presence of CtDsbB using gel-shift assay**

605 Purified reduced CtDsbA or CtDsbA-SSS (15 μ M) were mixed with equimolar amounts of
606 detergent solubilised purified CtDsbB (15 μ M) in the presence or absence of equimolar
607 amounts of UQ1 (15 μ M) in 25 mM MES pH 6, 150 mM NaCl, and 0.1% DDM in a total
608 volume of 60 μ L. 5 μ L samples were taken immediately after adding CtDsbB ($t = 0$ mins),
609 and then after 10, 20, 30, 60, 90 and 120 min incubation, before trichloroacetic acid (TCA)
610 10 % w/v mediated precipitation, washing with ice-cold acetone, labelling with 4-acetamido-
611 4'-maleimidylstilbene-2,2'-disulfonic acid (AMS) and SDS-PAGE analysis as described
612 previously [36]. Control reactions included reduced CtDsbA/CtDsbA-SSS with UQ1 (15 μ M),

613 CtDsbA/CtDsbA-SSS with 5 mM oxidised glutathione (GSSG), and CtDsbA/CtDsbA-SSS
614 with 5 mM DTT incubated for 2 hrs. Data presented is representative of three independent
615 experiments from three different purifications of recombinant CtDsbA, CtDsbA-SSS and
616 CtDsbB, expressed following independent transformations of *E. coli*.

617

618 **Relative stability of oxidised and reduced forms of CtDsbA-SSS**

619 The thermal stability of reduced and oxidised CtDsbA-SSS was determined by circular
620 dichroism using a Jasco J-810 circular dichroism (CD) spectropolarimeter. Measurements
621 were carried out with 10 μ M protein in 100 mM NaH₂PO₄/Na₂HPO₄, 0.1 mM EDTA, pH 7.0
622 in a 1 mm quartz cuvette. The unfolding was monitored as a change in molar ellipticity at
623 220 nm with a heat rate of 0.5 K/min from 298 K to 398 K. Plotted data shows mean and SD
624 for two biological replicates.

625

1. Landeta C, Boyd D, Beckwith J. Disulfide bond formation in prokaryotes. *Nature microbiology*. 2018;3(3):270-80. doi: 10.1038/s41564-017-0106-2. PubMed PMID: 29A73BA9-DDA3-4CAA-8E41-3F60A7D77591.
2. Jacob-Dubuisson F, Pinkner J, Xu Z, Striker R, Padmanhaban A, Hultgren SJ. PapD chaperone function in pilus biogenesis depends on oxidant and chaperone-like activities of DsbA. *Proceedings of the National Academy of Sciences of the United States of America*. 1994;91(24):11552-6. PubMed PMID: 7972100; PubMed Central PMCID: PMC45269.
3. Braun P, Ockhuijsen C, Eppens E, Koster M, Bitter W, Tommassen J. Maturation of *Pseudomonas aeruginosa* elastase. Formation of the disulfide bonds. 2001;276(28):26030-5. doi: 10.1074/jbc.M007122200.
4. Foreman DT, Martinez Y, Coombs G, Torres A, Kupersztoch YM. TolC and DsbA are needed for the secretion of STB, a heat-stable enterotoxin of *Escherichia coli*. *Mol Microbiol*. 1995;18(2):237-45. PubMed PMID: 8709843.
5. Hiniker A, Bardwell JC. In vivo substrate specificity of periplasmic disulfide oxidoreductases. *The Journal of Biological Chemistry*. 2004;279(13):12967-73. doi: 10.1074/jbc.M311391200. PubMed PMID: 14726535.
6. Miki T, Okada N, Kim Y, Abe A, Danbara H. DsbA directs efficient expression of outer membrane secretin EscC of the enteropathogenic *Escherichia coli* type III secretion apparatus. *Microb Pathog*. 2008;44(2):151-8. doi: 10.1016/j.micpath.2007.09.001. PubMed PMID: 17933489.
7. Heras B, Shouldice SR, Totsika M, Scanlon MJ, Schembri MA, Martin JL. DSB proteins and bacterial pathogenicity. *Nature reviews Microbiology*. 2009;7(3):215-25. doi: 10.1038/nrmicro2087. PubMed PMID: 19198617.
8. Abe M, Nakazawa T. The dsbB gene product is required for protease production by *Burkholderia cepacia*. *Infection and immunity*. 1996;64(10):4378-80. PubMed PMID: 8926116; PubMed Central PMCID: PMC174384.
9. Urban A, Leipelt M, Eggert T, Jaeger KE. DsbA and DsbC affect extracellular enzyme formation in *Pseudomonas aeruginosa*. *Journal of Bacteriology*. 2001;183(2):587-96. doi: 10.1128/JB.183.2.587-596.2001. PubMed PMID: 11133952; PubMed Central PMCID: PMC174384.
10. Zhang HZ, Donnenberg MS. DsbA is required for stability of the type IV pilin of enteropathogenic *Escherichia coli*. *Molecular microbiology*. 1996;21(4):787-97. PubMed PMID: 8878041.
11. Yu J, Webb H, Hirst TR. A homologue of the *Escherichia coli* DsbA protein involved in disulphide bond formation is required for enterotoxin biogenesis in *Vibrio cholerae*. *Molecular microbiology*. 1992;6(14):1949-58. PubMed PMID: 1324389.
12. Ireland PM, McMahon RM, Marshall LE, Halili M, Furlong E, Tay S, et al. Disarming *Burkholderia pseudomallei*: structural and functional characterization of a disulfide oxidoreductase (DsbA) required for virulence in vivo. *Antioxidants & redox signaling*. 2014;20(4):606-17. doi: 10.1089/ars.2013.5375. PubMed PMID: 23901809; PubMed Central PMCID: PMC3901323.
13. McMahon RM, Ireland PM, Sarovich DS, Petit G, Jenkins CH, Sarkar-Tyson M, et al. Virulence of the melioidosis pathogen *Burkholderia pseudomallei* requires the oxidoreductase membrane protein DsbB. *Infection and immunity*. 2018;IAI.00938-17. doi: 10.1128/IAI.00938-17. PubMed PMID: 29440370.
14. Totsika M, Heras B, Wurpel DJ, Schembri MA. Characterization of two homologous disulfide bond systems involved in virulence factor biogenesis in uropathogenic *Escherichia coli* CFT073. *Journal of Bacteriology*. 2009;191(12):3901-8. doi: 10.1128/JB.00143-09. PubMed PMID: 19376849; PubMed Central PMCID: PMC2698384.

- 674 15. Hackstadt T, Todd WJ, Caldwell HD. Disulfide-mediated interactions of the chlamydial
675 major outer membrane protein: role in the differentiation of chlamydiae? *Journal of Bacteriology*.
676 1985;161(1):25-31. PubMed PMID: 2857160; PubMed Central PMCID: PMC214830.
- 677 16. Stirling P, Allan I, Pearce JH. Interference with transformation of chlamydiae from
678 reproductive to infective body forms by deprivation of cysteine. *FEMS microbiology letters*.
679 1983;19(1):133-6. doi: 10.1111/j.1574-6968.1983.tb00526.x. PubMed PMID: 10.1111/j.1574-
680 6968.1983.tb00526.x.
- 681 17. Hatch TP, Allan I, Pearce JH. Structural and polypeptide differences between envelopes of
682 infective and reproductive life cycle forms of *Chlamydia* spp. *Journal of Bacteriology*.
683 1984;157(1):13-20. PubMed PMID: 6690419; PubMed Central PMCID: PMC215122.
- 684 18. Sardinia LM, Segal E, Ganem D. Developmental regulation of the cysteine-rich outer-
685 membrane proteins of murine *Chlamydia trachomatis*. *Journal of general microbiology*.
686 1988;134(4):997-1004. doi: 10.1099/00221287-134-4-997. PubMed PMID: 3183625.
- 687 19. Raulston JE, Davis CH, Paul TR, Hobbs JD, Wyrick PB. Surface accessibility of the 70-
688 kilodalton *Chlamydia trachomatis* heat shock protein following reduction of outer membrane protein
689 disulfide bonds. *Infection and immunity*. 2002;70(2):535-43. PubMed PMID: 11796580; PubMed
690 Central PMCID: PMC2127684.
- 691 20. Christensen S, McMahon RM, Martin JL, Huston WM. Life inside and out: making and
692 breaking protein disulfide bonds in *Chlamydia*. *Critical reviews in microbiology*. 2019;44:1-18. doi:
693 10.1080/1040841X.2018.1538933. PubMed PMID: 30663449.
- 694 21. Bavoil P, Ohlin A, Schachter J. Role of disulfide bonding in outer membrane structure and
695 permeability in *Chlamydia trachomatis*. *Infection and immunity*. 1984;44(2):479-85. PubMed PMID:
696 6715046; PubMed Central PMCID: PMC263545.
- 697 22. Hatch TP, Miceli M, Sublett JE. Synthesis of disulfide-bonded outer membrane proteins
698 during the developmental cycle of *Chlamydia psittaci* and *Chlamydia trachomatis*. *Journal of*
699 *Bacteriology*. 1986;165(2):379-85. PubMed PMID: 3944054; PubMed Central PMCID:
700 PMC214428.
- 701 23. Betts-Hampikian HJ, Fields KA. Disulfide bonding within components of the *Chlamydia* type
702 III secretion apparatus correlates with development. *Journal of Bacteriology*. 2011;193(24):6950-9.
703 doi: 10.1128/JB.05163-11. PubMed PMID: 22001510; PubMed Central PMCID: PMC3232835.
- 704 24. Bardwell JC, McGovern K, Beckwith J. Identification of a protein required for disulfide bond
705 formation in vivo. *Cell*. 1991;67(3):581-9. PubMed PMID: 1934062.
- 706 25. Kobayashi T, Kishigami S, Sone M, Inokuchi H, Mogi T, Ito K. Respiratory chain is required
707 to maintain oxidized states of the DsbA-DsbB disulfide bond formation system in aerobically
708 growing *Escherichia coli* cells. *Proceedings of the National Academy of Sciences of the United States*
709 *of America*. 1997;94(22):11857-62. PubMed PMID: 9342327; PubMed Central PMCID:
710 PMC23636.
- 711 26. Bader M, Muse W, Ballou DP, Gassner C, Bardwell JC. Oxidative protein folding is driven
712 by the electron transport system. *Cell*. 1999;98(2):217-27. PubMed PMID: 10428033.
- 713 27. Bader MW, Xie T, Yu CA, Bardwell JC. Disulfide bonds are generated by quinone reduction.
714 *The Journal of Biological Chemistry*. 2000;275(34):26082-8. doi: 10.1074/jbc.M003850200.
715 PubMed PMID: 10854438.
- 716 28. Martin JL, Bardwell JC, Kuriyan J. Crystal structure of the DsbA protein required for
717 disulphide bond formation in vivo. *Nature*. 1993;365(6445):464-8. doi: 10.1038/365464a0. PubMed
718 PMID: 8413591.
- 719 29. Chivers PT, Prehoda KE, Raines RT. The CXXC motif: a rheostat in the active site.
720 *Biochemistry*. 1997;36(14):4061-6.
- 721 30. Shouldice SR, Heras B, Walden PM, Totsika M, Schembri MA, Martin JL. Structure and
722 function of DsbA, a key bacterial oxidative folding catalyst. *Antioxidants & redox signaling*.
723 2011;14(9):1729-60. doi: 10.1089/ars.2010.3344. PubMed PMID: 21241169.

31. McMahon RM, Premkumar L, Martin JL. Four structural subclasses of the antivirulence drug target disulfide oxidoreductase DsbA provide a platform for design of subclass-specific inhibitors. *Biochimica et biophysica acta*. 2014;1844(8):1391-401. doi: 10.1016/j.bbapap.2014.01.013. PubMed PMID: 24487020.
32. Arts IS, Ball G, Leverrier P, Garvis S, Nicolaes V, Vertommen D, et al. Dissecting the machinery that introduces disulfide bonds in *Pseudomonas aeruginosa*. *mBio*. 2013;4(6):e00912-13. doi: 10.1128/mBio.00912-13. PubMed PMID: 24327342; PubMed Central PMCID: PMC3870256.
33. Kurz M, Iturbe-Ormaetxe I, Jarrott R, Shouldice SR, Wouters MA, Frei P, et al. Structural and functional characterization of the oxidoreductase alpha-DsbA1 from *Wolbachia pipientis*. *Antioxidants & redox signaling*. 2009;11(7):1485-500. doi: 10.1089/ARS.2008.2420. PubMed PMID: 19265485.
34. Premkumar L, Heras B, Duprez W, Walden P, Halili M, Kurth F, et al. Rv2969c, essential for optimal growth in *Mycobacterium tuberculosis*, is a DsbA-like enzyme that interacts with VKOR-derived peptides and has atypical features of DsbA-like disulfide oxidases. *Acta crystallographica Section D, Biological crystallography*. 2013;69(Pt 10):1981-94. doi: 10.1107/S0907444913017800. PubMed PMID: 24100317; PubMed Central PMCID: PMC3792642.
35. Chim N, Harmston CA, Guzman DJ, Goulding CW. Structural and biochemical characterization of the essential DsbA-like disulfide bond forming protein from *Mycobacterium tuberculosis*. *BMC Struct Biol*. 2013;13:23. doi: 10.1186/1472-6807-13-23. PubMed PMID: 24134223; PubMed Central PMCID: PMC3853704.
36. Christensen S, Groftehaug MK, Byriel K, Huston WM, Furlong E, Heras B, et al. Structural and Biochemical Characterization of *Chlamydia trachomatis* DsbA Reveals a Cysteine-Rich and Weakly Oxidising Oxidoreductase. *PLoS One*. 2016;11(12):e0168485. doi: 10.1371/journal.pone.0168485. PubMed PMID: 28030602; PubMed Central PMCID: PMC5193440.
37. Huston WM, Theodoropoulos C, Mathews SA, Timms P. *Chlamydia trachomatis* responds to heat shock, penicillin induced persistence, and IFN-gamma persistence by altering levels of the extracytoplasmic stress response protease HtrA. *BMC Microbiol*. 2008;8:190. doi: 10.1186/1471-2180-8-190. PubMed PMID: 18986550; PubMed Central PMCID: PMC2585093.
38. Newhall WJt. Biosynthesis and disulfide cross-linking of outer membrane components during the growth cycle of *Chlamydia trachomatis*. *Infection and immunity*. 1987;55(1):162-8. PubMed PMID: 3793227; PubMed Central PMCID: PMC260295.
39. Wang X, Schwarzer C, Hybiske K, Machen TE, Stephens RS. Developmental stage oxidoreductive states of *Chlamydia* and infected host cells. *mBio*. 2014;5(6):e01924. doi: 10.1128/mBio.01924-14. PubMed PMID: 25352618; PubMed Central PMCID: PMC4217174.
40. Inaba K, Murakami S, Suzuki M, Nakagawa A, Yamashita E, Okada K, et al. Crystal structure of the DsbB-DsbA complex reveals a mechanism of disulfide bond generation. *Cell*. 2006;127(4):789-801.
41. Zhou Y, Cierpicki T, Jimenez RH, Lukasik SM, Ellena JF, Cafiso DS, et al. NMR solution structure of the integral membrane enzyme DsbB: functional insights into DsbB-catalyzed disulfide bond formation. *Molecular cell*. 2008;31(6):896-908. doi: 10.1016/j.molcel.2008.08.028. PubMed PMID: 18922471; PubMed Central PMCID: PMC2622435.
42. Stamm M, Staritzbichler R, Khafizov K, Forrest LR. Alignment of Helical Membrane Protein Sequences Using AlignMe. *PloS one*. 2013;8(3):e57731. doi: 10.1371/journal.pone.0057731. PubMed PMID: 23469223; PubMed Central PMCID: PMC3587630.
43. Robert X, Gouet P. Deciphering key features in protein structures with the new ENDscript server. *Nucleic acids research*. 2014;42(Web Server issue):W320-4.
44. Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. *Journal of molecular biology*. 2001;305(3):567-80. doi: 10.1006/jmbi.2000.4315. PubMed PMID: 11152613.

45. Jander G, Martin NL, Beckwith J. Two cysteines in each periplasmic domain of the membrane protein DsbB are required for its function in protein disulfide bond formation. *The EMBO journal*. 1994;13(21):5121-7. PubMed PMID: 7957076; PubMed Central PMCID: PMC395459.
46. Inaba K, Ito K. Paradoxical redox properties of DsbB and DsbA in the protein disulfide-introducing reaction cascade. *The EMBO journal*. 2002;21(11):2646-54. doi: 10.1093/emboj/21.11.2646. PubMed PMID: 12032077; PubMed Central PMCID: PMC126043.
47. Ito K, Inaba K. The disulfide bond formation (Dsb) system. *Current opinion in structural biology*. 2008;18(4):450-8. doi: 10.1016/j.sbi.2008.02.002. PubMed PMID: 18406599.
48. Takahashi YH, Inaba K, Ito K. Characterization of the menaquinone-dependent disulfide bond formation pathway of *Escherichia coli*. *The Journal of Biological Chemistry*. 2004;279(45):47057-65. doi: 10.1074/jbc.M407153200. PubMed PMID: 15347648.
49. Walden PM, Halili MA, Archbold JK, Lindahl F, Fairlie DP, Inaba K, et al. The alpha-proteobacteria *Wolbachia pipientis* protein disulfide machinery has a regulatory mechanism absent in gamma-proteobacteria. *PLoS One*. 2013;8(11):e81440. doi: 10.1371/journal.pone.0081440. PubMed PMID: 24282596; PubMed Central PMCID: PMC3839904.
50. Belland RJ, Zhong G, Crane DD, Hogan D, Sturdevant D, Sharma J, et al. Genomic transcriptional profiling of the developmental cycle of *Chlamydia trachomatis*. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;100(14):8478-83. doi: 10.1073/pnas.1331135100. PubMed PMID: 12815105; PubMed Central PMCID: PMC166254.
51. Abreu IC, Guerra JF, Pereira RR, Silva M, Lima WG, Silva ME, et al. Hypercholesterolemic diet induces hepatic steatosis and alterations in mRNA expression of NADPH oxidase in rat livers. *Arq Bras Endocrinol Metabol*. 2014;58(3):251-9. PubMed PMID: 24863087.
52. Vogel H, Wheat CW. Accessing the transcriptome: how to normalize mRNA pools. *Methods Mol Biol*. 2011;772:105-28. doi: 10.1007/978-1-61779-228-1_6. PubMed PMID: 22065434.
53. Saka HA, Thompson JW, Chen Y-S, Kumar Y, Dubois LG, Moseley MA, et al. Quantitative proteomics reveals metabolic and pathogenic properties of *Chlamydia trachomatis* developmental forms. *Molecular microbiology*. 2011;82(5):1185-203. doi: 10.1111/j.1365-2958.2011.07877.x. PubMed PMID: 10.1111/j.1365-2958.2011.07877.x.
54. Nicholson TL, Olinger L, Chong K, Schoolnik G, Stephens RS. Global stage-specific gene regulation during the developmental cycle of *Chlamydia trachomatis*. *Journal of Bacteriology*. 2003;185(10):3179-89. PubMed PMID: 12730178; PubMed Central PMCID: PMC154084.
55. Mukhopadhyay S, Good D, Miller RD, Graham JE, Mathews SA, Timms P, et al. Identification of *Chlamydia pneumoniae* proteins in the transition from reticulate to elementary body formation. *Mol Cell Proteomics*. 2006;5(12):2311-8. doi: 10.1074/mcp.M600214-MCP200. PubMed PMID: 16921167.
56. Ellman GL, Courtney KD, Andres V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochemical pharmacology*. 1961;7:88-95.
57. Studier FW. Protein production by auto-induction in high-density shaking cultures. *Protein expression and purification*. 2005;41(1):207-34.